Investors
News
nCage Therapeutics and Ryvu have agreed to a research collaboration
A collaboration to develop a next-generation antibody-drug conjugate platform built on the TRAP-cage.
Read morenCage's CEO John Bason is presenting at Prague Bio
Proof of concept data showing a T cell response from programmed delivery of internal antigen.
Read morenCage Therapeutics to collaborate with the University of Nottingham on a novel Chagas vaccine
A collaboration agreement to develop a first-in-class vaccine against Chagas disease.
Read more